Ghost Tree Capital’s Gyre Therapeutics GYRE Stock Holding History

Ghost Tree Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-133,333	Closed	-$4.11M	–	59
2021 Q3	$4.11M	Hold	133,333	–	–	1.2%	33
2021 Q2	$4.33M	Hold	133,333	–	–	1.19%	32
2021 Q1	$5.04M	Buy	+133,333	New	+$6.09M	1.18%	30
2019 Q2	–	Sell	-13,333	Closed	-$811K	–	48
2019 Q1	$811K	Sell	13,333 -13,334	-50%	-$857K	0.21%	38
2018 Q4	$1.58M	Hold	26,667	–	–	0.57%	34
2018 Q3	$2.16M	Sell	26,667 -20,666	-44%	-$1.64M	0.46%	44
2018 Q2	$4.14M	Sell	47,333 -12,667	-21%	-$2.22M	1.22%	30
2018 Q1	$11.6M	Buy	+60,000	New	+$11.2M	2.35%	12

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Ghost Tree Capital's GYRE Position: Q4 2021 in Review

Ghost Tree Capital sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 133,333 shares — an estimated $4.11M sold.

Ghost Tree Capital first reported a position in GYRE in Q1 2018 and held it in 8 quarters. The position peaked at $11.6M in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

Ghost Tree Capital reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
Ghost Tree Capital sold 133,333 Gyre Therapeutics shares in Q4 2021, an estimated $4.11M.
Ghost Tree Capital first reported a position in Gyre Therapeutics in Q1 2018 and held it in 8 quarters.
Ghost Tree Capital's Gyre Therapeutics position peaked at $11.6M in Q1 2018.
51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Ghost Tree Capital's 13F filing for Q4 2021, filed 16 Feb 2022.